Council For High Blood Pressure Research Research Articles

Abstracts of the 22nd Annual Scientific Meeting of the High Blood Pressure Research Council of Australia Inc.

Abstracts of the 22nd Annual Scientific Meeting of the High Blood Pressure Research Council of Australia Inc.

Council Honorees and the Nobel Prize

This month we continue to celebrate the 20th Anniversary of Hypertension by honoring two more highly respected investigators who played important roles on the Council for High Blood Pressure Research (CHBPR). Again, each of the individuals that we honor was selected as a recipient of the Stouffer–Ciba–Novartis Award …

Council honorees and the nobel prize : our continued anniversary celebration

This month we continue to celebrate the 20th Anniversary of Hypertension by honoring two more highly respected investigators who played important roles on the Council for High Blood Pressure Research (CHBPR). Again, each of the individuals that we honor was selected as a recipient of the Stouffer–Ciba–Novartis Award …

Council honorees and the nobel prize : our continued anniversary celebration

This month we continue to celebrate the 20th Anniversary of Hypertension by honoring two more highly respected investigators who played important roles on the Council for High Blood Pressure Research (CHBPR). Again, each of the individuals that we honor was selected as a recipient of the Stouffer–Ciba–Novartis Award …

Proceedings of the High Blood Pressure Research Council of Australia

Proceedings of the High Blood Pressure Research Council of Australia

Second Australian National Blood Pressure Study (ANBP2): Australian Comparative Outcome Trial of ACE inhibitor- and Diuretic-based Treatment of Hypertension in the Elderly:Management Committee on behalf of the High Blood Pressure Research Council of Australia

The Second Australian National Blood Pressure Study (ANBP2) is a comparative outcome trial being conducted in general practices throughout Australia of ACE inhibitor- and diuretic-based treatment in 6000 hypertensive patients aged 65–34 years. The study is using a prospective randomised open-label design with blinding of endpoint assessments. The primary objective is to determine whether there is any difference in total cardiovascular events (fatal and non-fatal) over a five year treatment period between the two treatment regimens. Eligible hypertensive patients (average sitting blood pressure at the 2nd and 3rd screening visits > 160 mm Hg systolic and/or > 90 mm Hg diastolic) may be either untreated or previously treated and should have no history of recent cardiovascular morbidity or serious intercurrent illness. Patients are randomised to one of the treatment arms with randomisation stratified for practice and for age. Following randomisation each patient's blood pressure is managed by his/her general practitioner according to guidelines relevant to each treatment arm. Over 700 patients have now been randomised with recruitment intended to be complete by the end of 1997.

PROCEEDINGS OF THE HIGH BLOOD PRESSURE RESEARCH COUNCIL OF AUSTRALIA

Clinical and Experimental Pharmacology and PhysiologyVolume 11, Issue 4 p. 333-333 PROCEEDINGS OF THE HIGH BLOOD PRESSURE RESEARCH COUNCIL OF AUSTRALIA First published: August 1984 https://doi.org/10.1111/j.1440-1681.1984.tb00272.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume11, Issue4August 1984Pages 333-333 RelatedInformation